$EMCG
Embrace Change Acquisition Corp Stock $emcg

$emcg Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-Q Financial Statement

#000182912624005284 Filed on August 07, 2024

Income Statement

Concept	2024 Q1	2023 Q1
Revenue	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$49.80K	$128.3K
YoY Change	-61.17%
Operating Profit	-$49.80K	-$128.3K
YoY Change	-61.17%
Interest Expense	$735.6K	$822.3K
YoY Change	-10.55%
% of Operating Profit
Other Income/Expense, Net	$357.1K	$822.3K
YoY Change	-56.58%
Pretax Income	$307.3K	$694.1K
YoY Change	-55.73%
Income Tax
% Of Pretax Income
Net Earnings	$307.3K	$694.1K
YoY Change	-55.73%
Net Earnings / Revenue
Basic Earnings Per Share		-$0.07
Diluted Earnings Per Share	$0.04	-$0.07
COMMON SHARES
Basic Shares Outstanding	7.423M	9.689M
Diluted Shares Outstanding		9.689M

Balance Sheet

Concept	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$5.310K	$398.5K
YoY Change	-98.67%
Cash & Equivalents	$5.308K	$398.5K
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$5.308K	$398.5K
YoY Change	-98.67%
LONG-TERM ASSETS
Property, Plant & Equipment
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments	$57.27M	$77.36M
YoY Change	-25.98%
Other Assets
YoY Change
Total Long-Term Assets	$57.27M	$77.36M
YoY Change	-25.98%	44328.74%
TOTAL ASSETS
Total Short-Term Assets	$5.308K	$398.5K
Total Long-Term Assets	$57.27M	$77.36M
Total Assets	$57.27M	$77.76M
YoY Change	-26.35%	44557.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable		$280.3K
YoY Change
Accrued Expenses	$1.049M
YoY Change
Deferred Revenue
YoY Change
Short-Term Debt	$770.1K	$0.00
YoY Change		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$1.882M	$280.3K
YoY Change	571.4%	83.95%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$2.966M	$2.588M
YoY Change	14.63%
Total Long-Term Liabilities	$2.966M	$2.588M
YoY Change	14.63%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.882M	$280.3K
Total Long-Term Liabilities	$2.966M	$2.588M
Total Liabilities	$4.848M	$2.868M
YoY Change	69.04%	1811.84%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.843M	-$2.470M
YoY Change	96.1%	76355.42%
Common Stock	$230.00	$230.00
YoY Change	0.0%	22.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$4.842M	-$2.469M
YoY Change
Total Liabilities & Shareholders Equity	$57.27M	$77.76M
YoY Change	-26.35%	44557.59%

Cashflow Statement

Concept	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	$307.3K	$694.1K
YoY Change	-55.73%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$77.73K	-$4.529K
YoY Change	1616.16%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities	-$300.0K
YoY Change
Cash From Investing Activities	-$300.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$377.7K
YoY Change
NET CHANGE
Cash From Operating Activities	-$77.73K	-4.529K
Cash From Investing Activities	-$300.0K
Cash From Financing Activities	$377.7K
Net Change In Cash	$0.00	-4.529K
YoY Change	-100.0%
FREE CASH FLOW
Cash From Operating Activities	-$77.73K	-$4.529K
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital		usd
CY2023Q1	CIK0001869601	Loss On Modification Of Deferred Underwriting Commission LossOnModificationOfDeferredUnderwritingCommission		usd
CY2023Q1	CIK0001869601	Loss On Modification Of Deferred Underwriting Commission LossOnModificationOfDeferredUnderwritingCommission		usd
CY2024Q1	CIK0001869601	Increase Decrease In Other Receivable IncreaseDecreaseInOtherReceivable		usd
CY2023Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2023Q1	CIK0001869601	Proceeds From Convertible Promissory Note Related Party ProceedsFromConvertiblePromissoryNoteRelatedParty		usd
CY2023Q1	CIK0001869601	Proceeds From Related Party For Working Capital Purpose ProceedsFromRelatedPartyForWorkingCapitalPurpose		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities		usd
CY2023Q1	CIK0001869601	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable		usd
CY2023Q1	CIK0001869601	Extension Funds Attributable To Ordinary Shares To Redemption ExtensionFundsAttributableToOrdinarySharesToRedemption		usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	5308	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	5308	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	57266630	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	56231052	usd
CY2024Q1	us-gaap	Assets Assets	57271938	usd
CY2023Q4	us-gaap	Assets Assets	56236360	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1049333	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1077258	usd
CY2024Q1	CIK0001869601	Due To Related Party DueToRelatedParty	62260	usd
CY2023Q4	CIK0001869601	Due To Related Party DueToRelatedParty	54535	usd
CY2024Q1	CIK0001869601	Convertible Promissory Note Related Party ConvertiblePromissoryNoteRelatedParty	770112	usd
CY2023Q4	CIK0001869601	Convertible Promissory Note Related Party ConvertiblePromissoryNoteRelatedParty	400112	usd
CY2024Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1881705	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1531905	usd
CY2024Q1	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2966000	usd
CY2023Q4	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2024Q1	us-gaap	Liabilities Liabilities	4847705	usd
CY2023Q4	us-gaap	Liabilities Liabilities	4119404	usd
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2024Q1	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	11.17
CY2023Q4	us-gaap	Temporary Equity Redemption Price Per Share TemporaryEquityRedemptionPricePerShare	10.97
CY2024Q1	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	57266630	usd
CY2023Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	56231052	usd
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2295893	shares
CY2024Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2295893	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	2295893	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	2295893	shares
CY2024Q1	us-gaap	Common Stock Value CommonStockValue	230	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	230	usd
CY2024Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4842627	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-4114326	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4842397	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4114096	usd
CY2024Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	57271938	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	56236360	usd
CY2024Q1	CIK0001869601	Formation And Operating Costs FormationAndOperatingCosts	49800	usd
CY2023Q1	CIK0001869601	Formation And Operating Costs FormationAndOperatingCosts	-128263	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-49800	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-128263	usd
CY2024Q1	us-gaap	Investment Income Net InvestmentIncomeNet	735578	usd
CY2023Q1	us-gaap	Investment Income Net InvestmentIncomeNet	822317	usd
CY2024Q1	CIK0001869601	Loss On Modification Of Deferred Underwriting Commission LossOnModificationOfDeferredUnderwritingCommission	378501	usd
CY2024Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	357077	usd
CY2023Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	822317	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	307277	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	694054	usd
CY2024Q1	CIK0001869601	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	7423175	shares
CY2023Q1	CIK0001869601	Weighted Average Shares Outstanding Basic And Diluted WeightedAverageSharesOutstandingBasicAndDiluted	9688748	shares
CY2024Q1	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.04
CY2023Q1	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.07
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-4114096	usd
CY2024Q1	CIK0001869601	Adjustment To General Reserves Amount Deposited Into Trust Account Subject To Redemption AdjustmentToGeneralReservesAmountDepositedIntoTrustAccountSubjectToRedemption	-300000	usd
CY2024Q1	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	-735578	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-4842397	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-2341017	usd
CY2023Q1	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption RemeasurementOfOrdinarySharesSubjectToRedemption	-822317	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	694054	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-2469280	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	307277	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	694054	usd
CY2024Q1	CIK0001869601	Investment Income Earned On Investments Held In Trust Account InvestmentIncomeEarnedOnInvestmentsHeldInTrustAccount	735578	usd
CY2023Q1	CIK0001869601	Investment Income Earned On Investments Held In Trust Account InvestmentIncomeEarnedOnInvestmentsHeldInTrustAccount	822317	usd
CY2024Q1	CIK0001869601	Loss On Modification Of Deferred Underwriting Commission LossOnModificationOfDeferredUnderwritingCommission	378501	usd
CY2023Q1	CIK0001869601	Increase Decrease In Other Receivable IncreaseDecreaseInOtherReceivable	521	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-27925	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	123213	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-77725	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-4529	usd
CY2024Q1	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	300000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-300000	usd
CY2024Q1	CIK0001869601	Proceeds From Convertible Promissory Note Related Party ProceedsFromConvertiblePromissoryNoteRelatedParty	370000	usd
CY2024Q1	CIK0001869601	Proceeds From Related Party For Working Capital Purpose ProceedsFromRelatedPartyForWorkingCapitalPurpose	7725	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	377725	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-0	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4529	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5308	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	403012	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5308	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	398483	usd
CY2024Q1	CIK0001869601	Deferred Underwriting Fee Payable DeferredUnderwritingFeePayable	378501	usd
CY2024Q1	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption1 RemeasurementOfOrdinarySharesSubjectToRedemption1	735578	usd
CY2023Q1	CIK0001869601	Remeasurement Of Ordinary Shares Subject To Redemption1 RemeasurementOfOrdinarySharesSubjectToRedemption1	822317	usd
CY2024Q1	CIK0001869601	Extension Funds Attributable To Ordinary Shares To Redemption ExtensionFundsAttributableToOrdinarySharesToRedemption	300000	usd
CY2022Q3	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2022Q3	CIK0001869601	Deferred Underwriter Fees Payable Non Current DeferredUnderwriterFeesPayableNonCurrent	2587499	usd
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	20536	shares
CY2022Q3	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	75776764	usd
CY2022Q3	CIK0001869601	Restricted Investment Price Per Share RestrictedInvestmentPricePerShare	10.25	shares
CY2024Q1	CIK0001869601	Net Tangible Assets Required For Consummation Of Business Combination NetTangibleAssetsRequiredForConsummationOfBusinessCombination	5000001	usd
CY2024Q1	us-gaap	Share Price SharePrice	10.25
CY2023Q3	CIK0001869601	Description Of Business Combination Period DescriptionOfBusinessCombinationPeriod	must consummate a business combination (the “Combination Period”) twelve (12) times for an additional one (1) month each time, from August 12, 2023 (i.e. the end of 12 months from the consummation of its Initial Public Offering, the “Termination Date”) to August 12, 2024 (the “Extended Date”)
CY2023Q3	us-gaap	Payments To Acquire Restricted Investments PaymentsToAcquireRestrictedInvestments	100000	usd
CY2023Q3	us-gaap	Stock Redeemed Or Called During Period Shares StockRedeemedOrCalledDuringPeriodShares	1550710	shares
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2024Q1	CIK0001869601	Description Of Business Organization DescriptionOfBusinessOrganization	From August 2023 to December 2023, the Company deposited five tranches of $100,000, for an aggregated of $500,000 into the Trust Account, extending the Termination Date to January 12, 2024. From January 2024 to March 2024, the Company deposited additional three tranches of $100,000, for an aggregated of $300,000 into the Trust Account, extending the Termination Date to April 12, 2024. The Company has the right to extend the Combination Period four (4) more times for an additional one (1) month each time, from April 12, 2024 to August 12, 2024. On August 6, 2024, the Company deposited the required extension contributions of $400,000 into the Trust Account, to extend the Termination Date to August 12, 2024.
CY2024Q1	CIK0001869601	Dissolution Expense DissolutionExpense	50000	usd
CY2024Q1	us-gaap	Cash Cash	5308	usd
CY2023Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	159478	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_84E_eus-gaap--UseOfEstimates_zCuzOC97kACd" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_86C_za7Q3OGDO9wj">Use of Estimates</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Making estimates requires management to exercise significant judgment. It is at least reasonably possible that the estimate of the effect of a condition, situation or set of circumstances that existed at the date of the financial statements, which management considered in formulating its estimate, could change in the near term due to one or more future confirming events. Accordingly, the actual results could differ significantly from those estimates.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p>
CY2024Q1	us-gaap	Cash Cash	5308	usd
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2024Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	0	usd
CY2024Q1	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	57266630	usd
CY2023Q4	us-gaap	Assets Held In Trust Noncurrent AssetsHeldInTrustNoncurrent	56231052	usd
CY2024Q1	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2024Q1	CIK0001869601	Deferred Underwriter Fees Payable Non Current DeferredUnderwriterFeesPayableNonCurrent	2587499	usd
CY2024Q1	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	571245	usd
CY2024Q1	CIK0001869601	Accretion Of Offering Costs To Deficit AccretionOfOfferingCostsToDeficit	210873	usd
CY2022Q4	CIK0001869601	Temporary Equity Share Outstanding TemporaryEquityShareOutstanding	7392855	shares
CY2024Q1	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2023Q4	us-gaap	Temporary Equity Shares Outstanding TemporaryEquitySharesOutstanding	5127282	shares
CY2024Q1	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2024Q1	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0	usd
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84B_eus-gaap--ConcentrationRiskCreditRisk_zqGhopNZvi3i" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b><span id="xdx_862_zgaAWo0OZKaj">Concentration of Credit Risk</span></b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">Financial instruments that potentially subject the Company to concentration of credit risk consist of a cash account in a financial institution which, at times may exceed the Federal depository insurance coverage of $<span id="xdx_900_eus-gaap--CashFDICInsuredAmount_c20240331_pp0p0" title="Cash, FDIC insured amount">250,000</span>. As of March 31, 2024, the Company had not experienced losses on this account and management believes the Company is not exposed to significant risks on such account. As of March 31, 2024 and December 31, 2023, the Company had $<span id="xdx_90C_eus-gaap--Cash_iI_pp0p0_c20240331_zFs9J0zR5Fl6" title="Cash"><span id="xdx_906_eus-gaap--Cash_iI_pp0p0_c20231231_z09OX8iZ4BQ5" title="Cash">5,308</span></span> cash held in operating bank account.</p>
CY2024Q1	us-gaap	Cash Fdic Insured Amount CashFDICInsuredAmount	250000	usd
CY2024Q1	us-gaap	Cash Cash	5308	usd
CY2023Q4	us-gaap	Cash Cash	5308	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	307277	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	694054	usd
CY2024Q1	CIK0001869601	Denominator Weighted Average Number Of Ordinary Shares DenominatorWeightedAverageNumberOfOrdinaryShares	7423175	shares
CY2023Q1	CIK0001869601	Denominator Weighted Average Number Of Ordinary Shares DenominatorWeightedAverageNumberOfOrdinaryShares	9688748	shares
CY2024Q1	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.04
CY2023Q1	CIK0001869601	Basic And Diluted Net Income Per Ordinary Share BasicAndDilutedNetIncomePerOrdinaryShare	0.07
CY2022Q3	CIK0001869601	Incurred Offering Costs IncurredOfferingCosts	3898030	usd
CY2022Q3	CIK0001869601	Deferred Underwriter Fee Payable Non Current DeferredUnderwriterFeePayableNonCurrent	2587499	usd
CY2024Q1	CIK0001869601	Accretion Of Offering Costs To Deficit AccretionOfOfferingCostsToDeficit	210873	usd
CY2024Q1	CIK0001869601	Due To Related Party DueToRelatedParty	62260	usd
CY2023Q4	CIK0001869601	Due To Related Party DueToRelatedParty	54535	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	100000	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	190112	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes ConvertiblePromissoryNotes	100000	usd
CY2024Q1	us-gaap	Related Party Transaction Description Of Transaction RelatedPartyTransactionDescriptionOfTransaction	From January 2024 to March 31, 2024, the Company issued four unsecured promissory notes (together with the convertible promissory notes as described above, were called “Convertible Promissory Notes”) amounting to $100,000, $100,000 $100,000 and $70,000, respectively, for an aggregated of $370,000, to the Company's CFO. The Convertible Promissory Notes bear no interest and are repayable in full upon the consummation of the Company’s Business Combination. They are convertible at the CFO’s election upon the consummation of the Company’s Business Combination. Upon such election, the notes will convert, at a price of $10.00 per unit, into units identical to the private placement units issued in connection with the Company’s Initial Public Offering.
CY2024Q1	CIK0001869601	Promissory Note Related Party PromissoryNoteRelatedParty	770112	usd
CY2023Q4	CIK0001869601	Promissory Note Related Party PromissoryNoteRelatedParty	400112	usd
CY2024Q1	CIK0001869601	Convertible Promissory Notes Related Party ConvertiblePromissoryNotesRelatedParty	240112	usd
CY2023Q4	CIK0001869601	Convertible Promissory Notes Related Party ConvertiblePromissoryNotesRelatedParty	90112	usd
CY2024Q1	CIK0001869601	Underwriting Discount Percentage UnderwritingDiscountPercentage	0.0100	pure
CY2024Q1	CIK0001869601	Deferred Underwriting Commission Percentage DeferredUnderwritingCommissionPercentage	0.0350	pure
CY2024Q1	CIK0001869601	Unrestricted Shares UnrestrictedShares	200000	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	200000	shares
CY2024Q1	CIK0001869601	Fair Value FairValue	2216000	usd
CY2024Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	11.08
CY2024Q1	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	1837499	usd
CY2024Q1	CIK0001869601	Deferred Underwriting Commission DeferredUnderwritingCommission	378501	usd
CY2024Q1	CIK0001869601	Percenatge Of Gross Proceeds Of The Ordinary Shares PercenatgeOfGrossProceedsOfTheOrdinaryShares	0.0100	pure
CY2024Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000	shares
CY2024Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2024Q1	CIK0001869601	Ordinary Shares Of Initial Shareholders OrdinarySharesOfInitialShareholders	1437500	shares
CY2021Q4	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	0.50	shares
CY2024Q1	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares
CY2023Q4	us-gaap	Temporary Equity Shares Issued TemporaryEquitySharesIssued	5127282	shares

Files In Submission

Name	View Source	Status
0001829126-24-005284-index-headers.html	Edgar Link	pending
0001829126-24-005284-index.html	Edgar Link	pending
0001829126-24-005284.txt	Edgar Link	pending
0001829126-24-005284-xbrl.zip	Edgar Link	pending
cik0001869601-20240331.xsd	Edgar Link	pending
embracechange_10q.htm	Edgar Link	pending
embracechange_ex31-1.htm	Edgar Link	pending
embracechange_ex31-2.htm	Edgar Link	pending
embracechange_ex32-1.htm	Edgar Link	pending
embracechange_ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cik0001869601-20240331_def.xml	Edgar Link	unprocessable
cik0001869601-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
embracechange_10q_htm.xml	Edgar Link	completed
cik0001869601-20240331_cal.xml	Edgar Link	unprocessable
cik0001869601-20240331_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$EMCG
Embrace Change Acquisition Corp Stock $emcg

2024 Q1 Form 10-Q Financial Statement

#000182912624005284 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMCG Embrace Change Acquisition Corp Stock $emcg

2024 Q1 Form 10-Q Financial Statement

#000182912624005284 Filed on August 07, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$EMCG
Embrace Change Acquisition Corp Stock $emcg